Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan for preserved ejection fraction heart failure after acute myocardial infarction
ChiCTR2100042755Phase 4Recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) and myocardial infarction (MI) (2 arms), sponsored by Jiangmen Central Hospital. Primary endpoints: NT-proBNP, EF and 4 more. Started Feb 2021; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100042755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042755.